Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1083

  • The following term was ignored: (
  • See the search details.
1.

The role of adipose stroma in prostate cancer aggressiveness.

Kolonin MG, DiGiovanni J.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S348-S350. doi: 10.21037/tau.2019.04.07. No abstract available.

2.

An immediate, single instillation of mitomycin C in non-muscle invasive bladder cancer: can we define which patients do and do not benefit?

Bosschieter J, van Moorselaar RJA, Nieuwenhuijzen JA.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S346-S347. doi: 10.21037/tau.2019.03.08. No abstract available.

3.

Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale.

Sedhom R, Antonarakis ES.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S341-S345. doi: 10.21037/tau.2019.05.02. No abstract available.

4.

The risk of oversimplification in risk-stratification of neoadjuvant chemotherapy-responses in muscle invasive bladder cancer.

Sherif A.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S337-S340. doi: 10.21037/tau.2019.05.03. No abstract available.

5.

Prognosis in high-grade T1 bladder cancer: host immune response and tumour infiltrating lymphocytes.

Lee SM.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S335-S336. doi: 10.21037/tau.2019.05.06. No abstract available.

6.

Significant lack of urine-based biomarkers to replace cystoscopy for the surveillance of non-muscle invasive bladder cancer.

Miyake M, Owari T, Hori S, Fujimoto K.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S332-S334. doi: 10.21037/tau.2019.05.07. No abstract available.

7.

How to guide the selection of patients for trimodality therapy: the case for tumor immune and stromal signature.

Boeri L, Karnes RJ, Montanari E.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S329-S331. doi: 10.21037/tau.2019.05.10. No abstract available.

8.

Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answers.

Kool R, João Mansure J, Kassouf W.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S325-S328. doi: 10.21037/tau.2019.05.12. No abstract available.

9.

Looking into the clinical application of CD47-targeted near-infrared photoimmunotherapy for human bladder cancer treatment.

Kim J.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S322-S324. doi: 10.21037/tau.2019.05.13. No abstract available.

10.

The diagnosis of bladder cancer: are we missing a teachable moment for smoking cessation?

Sosnowski R, Kamecki H, Bjurlin MA, Przewoźniak K.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S318-S321. doi: 10.21037/tau.2019.05.15. No abstract available.

11.

Studying the impact of comorbidity on post radical cystectomy survival: have we come a full circle?

Regmi SK, Konety BR.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S314-S317. doi: 10.21037/tau.2019.06.06. No abstract available.

12.

Establishing and characterization of human and murine bladder cancer organoids.

Said N.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S310-S313. doi: 10.21037/tau.2019.06.05. No abstract available.

13.

Editorial: early PSA-testing after radical prostatectomy-the truth behind the scenes.

Hanske J, Roghmann F, Noldus J, Brock M.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S307-S309. doi: 10.21037/tau.2019.06.08. No abstract available.

14.

The docetaxel debate: impact of chemotherapy in high-risk non-metastatic prostate cancer.

Hurwitz MD.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S303-S306. doi: 10.21037/tau.2019.06.09. No abstract available.

15.

Bladder organoids: a step towards personalised cancer therapy?

Banerjee S, Southgate J.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S300-S302. doi: 10.21037/tau.2019.06.10. No abstract available.

16.

Editorial: assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer, a prospective single arm clinical study: California shows the way!

Choyke P.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S296-S299. doi: 10.21037/tau.2019.06.11. No abstract available.

17.

Molecular subtypes and response to immunotherapy in bladder cancer patients.

Todenhöfer T, Seiler R.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S293-S295. doi: 10.21037/tau.2019.06.21. No abstract available.

18.

Prognostic impact of tumor infiltrating lymphocytes in bladder urothelial carcinoma.

Kim HS, Ku JH.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S291-S292. doi: 10.21037/tau.2019.04.02. No abstract available.

19.

Perioperative mortality following radical cystectomy: the slippery slope of complications.

Nelson MH, Quek ML.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S289-S290. doi: 10.21037/tau.2019.02.04. No abstract available.

20.

Changes in testosterone prescribing patterns after FDA warning.

Lokeshwar SD, Bitran J, Ramasamy R.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S287-S288. doi: 10.21037/tau.2019.04.03. No abstract available.

Supplemental Content

Loading ...
Support Center